Janux Therapeutics (NASDAQ:JANX) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Janux Therapeutics (NASDAQ:JANX) in a report released on Monday, Benzinga reports. Cantor Fitzgerald currently has a $100.00 price target on the stock.

JANX has been the subject of several other reports. HC Wainwright reissued a buy rating and set a $63.00 price objective on shares of Janux Therapeutics in a report on Monday, August 19th. Stifel Nicolaus started coverage on shares of Janux Therapeutics in a research report on Friday, September 6th. They set a buy rating and a $70.00 price target for the company. Scotiabank cut their price objective on shares of Janux Therapeutics from $47.00 to $42.00 and set a sector perform rating on the stock in a report on Friday, August 9th. Finally, Wedbush reaffirmed an outperform rating and issued a $74.00 price objective on shares of Janux Therapeutics in a research note on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Janux Therapeutics currently has an average rating of Moderate Buy and a consensus target price of $66.13.

Janux Therapeutics Stock Performance

Shares of JANX opened at $49.98 on Monday. The company has a market cap of $2.59 billion, a price-to-earnings ratio of -40.97 and a beta of 3.57. The stock has a fifty day moving average price of $43.28 and a two-hundred day moving average price of $44.19. Janux Therapeutics has a 52-week low of $5.65 and a 52-week high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.20. The firm had revenue of $8.90 million for the quarter, compared to analyst estimates of $0.77 million. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. The firm’s revenue was up 709.1% compared to the same quarter last year. As a group, research analysts predict that Janux Therapeutics will post -1.18 EPS for the current fiscal year.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of Janux Therapeutics stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $42.00, for a total value of $4,551,330.00. Following the transaction, the insider now owns 3,162,851 shares of the company’s stock, valued at $132,839,742. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last three months, insiders sold 268,578 shares of company stock worth $12,071,151. 35.40% of the stock is owned by company insiders.

Institutional Trading of Janux Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC raised its holdings in shares of Janux Therapeutics by 1.8% in the first quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company’s stock valued at $73,961,000 after purchasing an additional 34,069 shares during the last quarter. Vanguard Group Inc. increased its stake in Janux Therapeutics by 38.6% in the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after buying an additional 378,477 shares during the last quarter. Logos Global Management LP lifted its position in Janux Therapeutics by 400.0% during the 2nd quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock worth $31,418,000 after buying an additional 600,000 shares in the last quarter. Lord Abbett & CO. LLC acquired a new position in shares of Janux Therapeutics during the 1st quarter worth about $20,420,000. Finally, Samlyn Capital LLC grew its holdings in shares of Janux Therapeutics by 9.6% in the 2nd quarter. Samlyn Capital LLC now owns 324,703 shares of the company’s stock valued at $13,602,000 after acquiring an additional 28,312 shares in the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.